GlassScriptPhysician profile
Shane D Bush
NPI 1316258874
$19,628.29
in general payments reported to CMS, 2019-2025
58 companies · $1,010 in 2025
The $1,010 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,178 · 2020: $2,484 · 2021: $4,231 · 2022: $2,359 · 2023: $1,778 · 2024: $1,588 · 2025: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,376.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $3,993.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $1,794.87 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,430.20 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $1,149.66 | 2019-2022 | |
| Novo Nordisk INC | $1,046.02 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $889.47 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $860.45 | 2019-2025 | |
| Lilly USA, LLC | $843.13 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $719.27 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $599.03 | 2019-2025 | Austedo Xr, Ajovy |
| Allergan, INC. | $498.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $464.91 | 2019-2022 | |
| Esperion Therapeutics, INC. | $411.50 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $384.71 | 2020-2024 | |
| Glaxosmithkline, LLC. | $344.48 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Bush listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.